BioPharma Resources

Drug Trial Radar · NCT06294288

A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants

To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of LP-003 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Jul 13, 2022

Primary completion

Mar 4, 2024

Study completion Mar 4, 2024

Sponsor

Lead sponsor
Longbio PharmaIndustry
Sponsor type
Industry
First posted
Mar 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-003 and Part 2, multiple ascending dose (MAD).

Conditions

  • Chronic Spontaneous Urticaria

Interventions

  • LP-003 Dose 1 (Single)Biological

    A single dose of LP-003 (Dose 1) was administered intravenously.

  • LP-003 Dose 2 (Single)Biological

    A single dose of LP-003 (Dose 2) was administered intravenously.

  • LP-003 Dose 3 (Single)Biological

    A single dose of LP-003 (Dose 3) was administered intravenously.

  • LP-003 Dose 4 (Single)Biological

    A single dose of LP-003 (Dose 4) was administered intravenously.

  • LP-003 Dose 5 (Single)Biological

    A single dose of LP-003 (Dose 5) was administered intravenously.

  • Placebo (Single)Biological

    A single dose of placebo was administered intravenously.

  • LP-003 Dose 6 (Multiple)Biological

    LP-003 (Dose 6) was administered multiple times subcutaneously.

  • LP-003 Dose 7 (Multiple)Biological

    LP-003 (Dose 7) was administered multiple times subcutaneously.

  • LP-003 Dose 8 (Multiple)Biological

    LP-003 (Dose 8) was administered multiple times subcutaneously.

  • Placebo (Multiple)Biological

    Placebo was administered multiple times subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: Observation for 280 days after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.